Actively Recruiting
Exploring Safety and Effects of Vorinostat for Rett Syndrome Using an Individualized N of 1 Study Design
Led by Unravel Biosciences, Inc. · Updated on 2026-09-17
15
Participants Needed
1
Research Sites
10 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of vorinostat, an oral drug, in treating Rett syndrome, a rare neurodevelopmental disorder mostly affecting females due to MECP2 gene mutations. This exploratory, phase 1 trial uses an N of 1 design where each participant serves as her own control to better understand how vorinostat might influence symptoms and gene expression. The study aims to confirm safety, tolerability, and potential clinical and molecular benefits of the drug. Participants will receive daily oral doses starting with a 4-week placebo phase, followed by two vorinostat treatment phases 8 weeks at 80mgm2day and then 8 weeks at 160mgm2day, with dose escalation every 8 weeks. The trial is single-blinded so patients and caregivers wont know the treatment phase, while investigators and staff will. Up to 15 female patients aged 6 to 21 years with typical Rett syndrome will take part. During the 20-week study, participants will be monitored through clinical exams, caregiver questionnaires, and laboratory tests including RNA sequencing to assess changes in gene expression. Safety will be tracked by recording adverse events and treatment discontinuations. Other assessments include measuring motor skills, behavior, sleep habits, gastrointestinal symptoms, and seizure frequency. Participants will wear an actigraphy device to log activity levels, and caregivers will provide impressions of improvement throughout the trial.
CONDITIONS
Brief Title
Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome
Research Team
N
Neal I Muni, M.D., MSPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here